comparemela.com

Latest Breaking News On - Humacyte daily - Page 1 : comparemela.com

Humacyte (NASDAQ:HUMAW) Shares Down 6 5%

Humacyte, Inc. (NASDAQ:HUMAW – Get Free Report) shares fell 6.5% during mid-day trading on Tuesday . The company traded as low as $1.54 and last traded at $2.02. 47,419 shares traded hands during mid-day trading, an increase of 89% from the average session volume of 25,113 shares. The stock had previously closed at $2.16. Humacyte […]

Brady W Dougan Buys 2,362 Shares of Humacyte, Inc (NASDAQ:HUMA) Stock

Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) Director Brady W. Dougan purchased 2,362 shares of the business’s stock in a transaction that occurred on Tuesday, June 4th. The shares were purchased at an average cost of $6.35 per share, with a total value of $14,998.70. Following the completion of the acquisition, the director now directly […]

Humacyte (NASDAQ:HUMA) Hits New 1-Year High at $7 80

Humacyte (NASDAQ:HUMA) Hits New 1-Year High at $7 80
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

Head-To-Head Survey: Novozymes A/S (OTCMKTS:NVZMY) and Humacyte (NASDAQ:HUMA)

Humacyte (NASDAQ:HUMA – Get Free Report) and Novozymes A/S (OTCMKTS:NVZMY – Get Free Report) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations. Analyst Ratings This is a breakdown of recent ratings […]

Humacyte (NASDAQ:HUMA) Sets New 12-Month High at $7 80

Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) hit a new 52-week high on Wednesday . The stock traded as high as $7.80 and last traded at $7.76, with a volume of 573253 shares. The stock had previously closed at $7.49. Analyst Upgrades and Downgrades HUMA has been the topic of several recent research reports. Cantor […]

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.